Hemogenyx Pharmaceuticals (HEMO)

Sector:

Pharma and Biotech

Trade now with BarclaysStockbrokers Trade now with Barclays Sponsored by Barclays Stockbrokers

2.40p
   
  • Change Today:
      0.100p
  • 52 Week High: 4.90
  • 52 Week Low: 1.95
  • Currency: UK Pounds
  • Shares Issued: 356.04m
  • Volume: 757,882
  • Market Cap: 8.55m
  • RiskGrade: 281
  • Beta: 0.00

HEMO Overview

Hemogenyx Pharmaceuticals Plc is a biotechnology company developing novel therapies to transform bone marrow and blood stem cell transplantation, announces the readmission of its enlarged issued share capital to the standard listing segment of the Official List and to trading on the main market for listed securities of the London Stock Exchange. The Company is the holding company for Hemogenyx LLC, a US-based biotechnology company developing therapies to transform bone marrow and blood stem cell transplantation. These therapies will replace the need for existing methods of preparation of patients for a transplantation such as chemotherapy and radiation treatments, and will address the problem of finding a matching stem cell donor and reduce the risk of blood stem cell rejection after transplantation.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a n/a
Pr/Book 8.9  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

HEMO Fundamentals

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
28-Feb-15 n/a (0.01) (0.40)p n/a n/a n/a n/a 0.0%
31-Dec-15 n/a 0.08 0.60p 6.3 n/a n/a n/a 0.0%
31-Dec-16 n/a (0.47) (0.70)p n/a n/a n/a n/a 0.0%
31-Dec-17 n/a (2.41) (0.91)p n/a n/a n/a n/a 0.0%
31-Dec-18 n/a (1.52) (0.41)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Latest HEMO Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

HEMO Market Data

Currency UK Pounds
Share Price 2.40p
Change Today 0.100p
% Change 4.35 %
52 Week High 4.90
52 Week Low 1.95
Volume 757,882
Shares Issued 356.04m
Market Cap 8.55m
Beta 0.00
RiskGrade 281

HEMO Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
41.87% below the market average41.87% below the market average41.87% below the market average41.87% below the market average41.87% below the market average
72.41% below the sector average72.41% below the sector average72.41% below the sector average72.41% below the sector average72.41% below the sector average
Price Trend
65.94% below the market average65.94% below the market average65.94% below the market average65.94% below the market average65.94% below the market average
31.15% below the sector average31.15% below the sector average31.15% below the sector average31.15% below the sector average31.15% below the sector average
Income Not Available
Growth Not Available

HEMO Dividends

No dividends found

Trades for 21-May-2019

Time Volume / Share Price
16:14 3,882 @ 2.30p
16:12 350,000 @ 2.38p
12:16 150,000 @ 2.50p
10:40 50,000 @ 2.50p
09:31 95,000 @ 2.50p

HEMO Key Personnel

CEO Vladislav Sandler Ph.D.

Top of Page